87 reports

  • 2.5 EPIDEMIOLOGICAL FORECAST FOR OVARIAN CANCER (2015-2025)
  • 2.5.1 Diagnosed Incident Cases of Ovarian Cancer
  • Ovarian Cancer
  • Japan
  • United States
  • World
  • Forecast

Key Features of the Report: - Ovarian Cancer Patient Flow - Ovarian Cancer Prevalence - Ovarian Cancer Diagnosed Patients - Ovarian Cancer Treated Patients

  • Ovarian Cancer
  • Europe
  • France
  • World
  • Forecast

Ovarian cancer Market Forecast ($), Japan, 2015 – 2020 The latest research from Fore Pharma, Global Ovarian cancer Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Ovarian cancer pipeline products,

  • Ovarian Cancer
  • France
  • Germany
  • Italy
  • Market Size
  • ANALYSIS BY TYPE OF OVARIAN CANCER
  • Ovarian cancer gene therapy molecules by type of ovarian cancer
  • Ovarian Cancer
  • United States
  • Advantagene, Inc.
  • Celsion Corporation
  • Takara Bio Inc.

Key Features of the Report: - Ovarian Cancer Patient Flow - Ovarian Cancer Prevalence - Ovarian Cancer Diagnosed Patients - Ovarian Cancer Treated Patients

  • Ovarian Cancer
  • Europe
  • France
  • Germany
  • Forecast

Epithelial Ovarian Cancer - Epidemiology Forecast to 2027 ##.

  • Ovarian Cancer
  • France
  • Germany
  • Italy
  • Spain

Epithelial Ovarian Cancer : ##MM Market Analysis ##. ##. ##MM Market Size of Epithelial Ovarian Cancer ##. ##. ##MM Percentage Share of drugs marketed for Epithelial Ovarian Cancer ##. ##. ##MM Market Sales of Epithelial Ovarian Cancer by

  • Cancer
  • Ovarian Cancer
  • Pathology

Ovarian cancer Market Forecast ($), UK, 2015 – 2020 The latest research from Fore Pharma, Europe Ovarian cancer Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Ovarian cancer pipeline products,

  • Ovarian Cancer
  • Europe
  • France
  • Germany
  • Market Size

Japan Ovarian cancer Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Ovarian cancer Treatments ##) Ovarian cancer Pipeline ##) Japan Ovarian cancer Epidemiology ##) Marke

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Japan
  • Market Size

France Ovarian cancer Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Ovarian cancer Treatments ##) Ovarian cancer Pipeline ##) France Ovarian cancer Epidemiology ##) Mar

  • Cancer
  • Ovarian Cancer
  • Pathology
  • France
  • Market Size

UK Ovarian cancer Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Ovarian cancer Treatments ##) Ovarian cancer Pipeline ##) UK Ovarian cancer Epidemiology ##) Marketed Dr

  • Cancer
  • Ovarian Cancer
  • Pathology
  • United Kingdom
  • Market Size

Italy Ovarian cancer Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Ovarian cancer Treatments ##) Ovarian cancer Pipeline ##) Italy Ovarian cancer Epidemiology ##) Marke

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Italy
  • Market Size

Germany Ovarian cancer Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Ovarian cancer Treatments ##) Ovarian cancer Pipeline ##) Germany Ovarian cancer Epidemiology ##) M

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Germany
  • Market Size

US Ovarian cancer Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Ovarian cancer Treatments ##) Ovarian cancer Pipeline ##) US Ovarian cancer Epidemiology ##) Marketed Dr

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Market Size

Spain Ovarian cancer Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Ovarian cancer Treatments ##) Ovarian cancer Pipeline ##) Spain Ovarian cancer Epidemiology ##) Marke

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Spain
  • Market Size
  • 4.3.5 Ovarian Cancer Testing Market and Forecast
  • GLOBAL - OVARIAN CANCER TESTING MARKET (MILLION US$), 2010 - 2015
  • Ovarian Cancer
  • World
  • Forecast
  • bioMerieux S.A.
  • Cepheid

Welcome to having the world of ovarian cancer at your fingertips with " Target Atlas in Ovarian Cancer: A Competitive Outlook"!

  • Cancer
  • Ovarian Cancer

Recurrent Disease: Platinum-Resistant ## Figure ##: Ovarian Cancer Therapeutics, Global, Treatment Use Patterns and Market Size, 2013–2020 ## Figure ##: Ovarian Cancer Therapeutics, India, Treatment Use Patterns (‘##), 2013–2020 ## Figure ##: Ovarian

  • Cancer
  • Ovarian Cancer
  • Therapy
  • World
  • Forecast
  • Ovarian Cancer Treatment Drugs Sales Volume (million yuan)
  • CHAPTER IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND
  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Shenzhen Main Luck Pharmaceuticals Inc.

Drug Analysis: Rubraca

9091 10000 7727

Drug Analysis: Rubraca Product Profiles Rubraca : Prostate cancer Rubraca : Ovarian cancer LIST OF FIGURES Figure ##: Rubraca for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Rubraca for prostate cancer Fig

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Europe
  • United States
  • UK incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Japan Incidence of ovarian cancer by 5-yr age cohort, females (000s)
  • Cancer
  • Ovarian Cancer
  • Asia
  • Europe
  • North America
  • Ovarian Cancer Treatment Drugs Sales Volume (million yuan)
  • CHAPTER IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND
  • Ovarian Cancer
  • China
  • ACON Biotech Co., Ltd
  • Bayer Schering Pharmaceutical Co., Ltd
  • Ltd Jiangsu Hengrui Medicine Co.

Estrogen signaling is involved in a number of diseases with big market indications such as breast cancer, prostate cancer and osteoporosis.

  • Ovarian Cancer
  • China
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • Shenzhen Main Luck Pharmaceuticals Inc.
  • 5.14 OVARIAN CANCER
  • Treatment Guidelines for Ovarian Cancer in the 7MM
  • Ovarian Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group
  • Cerulean Pharma Product
  • METASTATIC/LOCALLY RECURRENT BREAST CANCER
  • Ovarian Cancer
  • Topical Delivery
  • United States
  • Forecast
  • Nektar Therapeutics
  • IMMUNOASSAY - OVARIAN CANCER - PRODUCT DESCRIPTION
  • EARLYCDT - OVARIAN CANCER - PRODUCT DESCRIPTION
  • Biomarker
  • Clinical Trial
  • Ovarian Cancer
  • United States
  • GlobalData's company
  • Latest Clinical Trials News on Metastatic Ovarian Cancer
  • METASTATIC OVARIAN CANCER THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY TRIAL STATUS, 2017*
  • Clinical Trial
  • Monoclonal Antibody
  • Ovarian Cancer
  • World
  • Product Initiative
  • Metastatic Ovarian Cancer Overview
  • Metastatic Ovarian Cancer - Discontinued Products
  • Cancer
  • Ovarian Cancer
  • Pharmaceutical
  • United States
  • Product Initiative
  • Epithelial Ovarian Cancer Overview
  • Epithelial Ovarian Cancer - Discontinued Products
  • Monoclonal Antibody
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • Metastatic Ovarian Cancer Overview
  • Metastatic Ovarian Cancer - Dormant Projects
  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Cellceutix Corporation